Gujarat Kidney and Super Speciality share price
NSE: GKSLBSE: 544666Healthcare ServicesSmall Cap
Gujarat Kidney and Super Speciality Limited · Face value ₹2 Face value. The nominal value of one share as the company issued it, the unit its share capital is counted in and a dividend can be stated as a percentage of; it has no link to the share price. Face value in the glossary · Listed Dec 2025 · Issue price ₹114
Last close ₹171.50down ₹2.85 (1.63%)BSE ₹171.45
Share price at the NSE close on 28 Oct 2026. Previous close ₹174.35.
28 Oct: open ₹175.51, high ₹175.51, low ₹170.61
Range of traded prices from listing on 30 Dec 2025 to 28 Oct 2026
₹98.36Low, 23 Jan 2026₹209.80High, 1 Oct 2026
- Next results date: the board meets on 4 Nov 2026 to consider: financial results. The notice · Results calendar
- Market capMarket capitalisation. Share price times the number of shares: what the whole company is worth at the day's price. The rank is by average market value over the six months to Jun 2026, among listed companies. Market capitalisation: how it is worked out
- ₹1,352 Cr1,531st largest listed
- P/EPrice to earnings, trailing. Market cap divided by the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, after the share of the other owners of its subsidiaries: what investors pay for each rupee of a year's profit. Price to earnings, trailing: how it is worked out
- Earlier quarters restated in the year
- P/BPrice to book. Market cap divided by the net worth that belongs to the company's own shareholders, its assets less everything it owes and less the other owners' share of its subsidiaries, on its latest balance sheet. Price to book: how it is worked out
- 5.35
- Dividend yieldDividend yield. Dividends paid per share in the twelve months to the day, as a percentage of the day's share price.
- Nonesince listing in Dec 2025
- ROCEReturn on capital employed. Operating profit after depreciation (revenue less operating expenses and depreciation, without other income and one-off items) as a percentage of all the money the business runs on: the whole group's net worth, the other owners of its subsidiaries included, plus borrowings. Lease liabilities are not counted: the results filings do not state them. The profit is over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly); net worth and borrowings are on the latest balance sheet.
- 8.0%
- Debt to equityDebt to equity. Borrowings divided by the whole group's net worth, the other owners of its subsidiaries included: rupees borrowed for each rupee of equity in the business. Lease liabilities are not counted: the results filings do not state them. From the balance sheet at the end of Mar 2026.
- 0.06
- Volume, NSEVolume. Shares traded on the last trading day; delivery is the part buyers kept rather than sold again the same day. Volume in the glossary
- 2,43,12349.5% delivered
Results
Consolidated; ₹ crore.Gujarat Kidney and Super Speciality quarterly results
Quarter to Jun 2026, against the quarter before
- RevenueRevenue. The pill is the change in revenue against the quarter before: this period's figure divided by that one's, less one, in per cent.
- ₹34 Crup 12.14%
- Net profitNet profit. The pill is the change in net profit against the quarter before: this period's figure divided by that one's, less one, in per cent. Net profit in the glossary
- ₹5.32 Crup 10.26%
- Net marginNet margin. Net profit as a percentage of revenue: how much of each rupee of sales is left after every cost, interest and tax. Net margin in the glossary
- 15.5%
Revenue by quarter
Peak revenue ₹34 Cr, quarter to Jun 2026; lowest ₹13 Cr, quarter to Sep 2025
Net profit by quarter, a loss in red
| ₹ crore | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|
| Revenue | 15.3 | 12.9 | 23.2 | 30.6 | 34.3 |
| Net profit | 5.4 | 2.9 | 3.7 | 4.8 | 5.3 |
| Net margin | 35.4% | 22.2% | 15.9% | 15.8% | 15.5% |
Consolidated. The 5 quarters from Jun 2025, the first on record. The latest is shaded. Net profit is the whole group's, the other owners of its subsidiaries included; P/E and ROE use the company's own share.
Year to Mar 2026
- Revenue
- ₹82 Cr
- Net profit
- ₹17 Cr
- Net margin
- 20.5%
| ₹ crore | Mar 2026 |
|---|---|
| Revenue | 82.0 |
| Net profit | 16.8 |
| Net margin | 20.5% |
Consolidated. Years to March. Net profit is the whole group's, the other owners of its subsidiaries included; P/E and ROE use the company's own share.
Business segments
In the year to Mar 2026 the company reports one business segment, HEALTHCARE INDUSTRY, which carries all its revenue.
Mutual fund holdings
2 funds disclosed a holding for Sep 2026. What they did in Sep 2026, against each fund's month before. 2 of the 2 funds that added or cut are index funds, ETFs or arbitrage funds: an index fund or ETF holds what its index holds, and an arbitrage fund holds the share against a sale of its future.
- AddedAdded. Funds that held more shares than at the end of the month before.
- 2
| Fund | |||
|---|---|---|---|
 Motilal Oswal BSE Healthcare ETFMotilal Oswal Mutual Fund | 615 | 0.02% | ₹0.01 Cr |
 Bandhan BSE Healthcare Index FundBandhan Mutual Fund | 290 | 0.02% | ₹52,000 |
Portfolios disclosed for Sep 2026. Weight is the holding as a share of the fund's assets.
Gujarat Kidney and Super Speciality competitors and peers
Hospital, 40 listed companies, priced on 28 Oct 2026. The table lists the 8 companies closest to Gujarat Kidney and Super Speciality in market cap.Healthcare companies
Gujarat Kidney and Super Speciality is not on the chart: it has no P/E or return on equity today
| Company | ||||||||
|---|---|---|---|---|---|---|---|---|
 Artemis Medicare ServicesARTEMISMED | 4,726 | 41.59 | 5.06 | +15.0% | +30.3% | 12.8% | 13.2% | 0.15% |
 Indraprastha Medical CorporationINDRAMEDCO | 2,875 | 15.29 | 3.88 | +10.9% | +12.1% | 28.1% | 30.8% | 1.28% |
 Dr Agarwals Eye HospitalDRAGARWQ | 2,471 | 32.41 | 7.13 | +20.0% | +31.9% | 27.4% | 24.5% | 0.14% |
 K M C Speciality Hospitals (India)KMCSHIL | 2,452 | 43.97 | 11.65 | +35.1% | +137.8% | 29.8% | 27.5% | 0.00% |
 ShalbySHALBY | 1,325 | 33.71 | 1.32 | +6.5% | – | 3.9% | 4.6% | 0.00% |
 GPT HealthcareGPTHEALTH | 1,103 | 23.34 | 4.10 | +18.1% | −0.8% | 18.3% | 22.1% | 1.86% |
 Unihealth HospitalsUNIHEALTH | 969 | 37.51 | – | +137.4% | +70.6% | 21.4% | 19.9% | 0.00% |
 Rays of BeliefMOMSBELIEF | 511 | – | – | – | – | – | – | 0.00% |
Market cap in ₹ crore. Growth is the last twelve months against the twelve before. A figure is left empty where it would rest on a loss or the company has under a year of results on record. ROE is the shareholders' profit over their net worth. ROCE is profit before interest and tax over the whole group's net worth plus borrowings, as in the figures at the top of the page.
Latest announcements
Routine notices left out.Gujarat Kidney and Super Speciality announcements
Oct 2026
28 Oct · Analysts
23 Oct · Board meeting
Sep 2026
28 Sep · Meeting
1 Sep · General Updates
Gujarat Kidney and Super Speciality annual report, year to Mar 2026
Gujarat Kidney and Super Speciality share price by year
Each calendar year to 2025.Gujarat Kidney and Super Speciality share price history
| Year | Close at year end | Change | Highest close | Lowest close |
|---|---|---|---|---|
| 2025 | 102.97 | – | 104.54 | 102.97 |
₹ per share, adjusted for splits and bonuses since. Change is on the close at the end of the year before. 2025 is from its first session, 30 Dec 2025.
Recent sessions
The 9 trading days to 27 Oct 2026, as traded on NSE; the latest is at the top of the page.
| Date | Open | High | Low | Close | Average price | Volume | Delivery |
|---|---|---|---|---|---|---|---|
| 27 Oct 2026 | 178.00 | 179.85 | 173.65 | 174.35 | 177.36 | 8,27,427 | 60.6% |
| 26 Oct 2026 | 177.67 | 179.84 | 174.71 | 177.57 | 177.82 | 7,06,545 | 71.7% |
| 23 Oct 2026 | 181.90 | 182.00 | 171.81 | 176.45 | 175.59 | 5,64,915 | 40.6% |
| 22 Oct 2026 | 183.86 | 183.86 | 178.03 | 179.46 | 180.31 | 2,67,305 | 47.4% |
| 21 Oct 2026 | 187.67 | 192.95 | 182.00 | 183.89 | 184.87 | 3,00,709 | 71.0% |
| 19 Oct 2026 | 187.02 | 191.00 | 186.02 | 187.76 | 189.06 | 4,35,243 | 52.8% |
| 16 Oct 2026 | 190.41 | 193.39 | 186.56 | 187.37 | 190.32 | 3,37,241 | 34.3% |
| 15 Oct 2026 | 194.69 | 196.80 | 188.00 | 189.64 | 191.01 | 3,01,217 | 49.6% |
| 14 Oct 2026 | 186.78 | 196.18 | 185.12 | 194.69 | 194.11 | 9,84,251 | 35.3% |
Prices in ₹ per share as traded, not adjusted.
Company details
- Chairperson and managing director
- Pragnesh Yashwantsinh Bharpoda
- At the end of the quarter to Sep 2026
- NSE symbol
- GKSL
- BSE code
- 544666
- ISIN
- INE0V0W01025
- Industry
- Healthcare Services
- CIN
- U85300GJ2019PLC111559
- Corporate identity number, the registrar of companies' code for it
- Incorporated
- 2019
- Registered office
- Plot No. 1, City Sarve No. 1537/A, Jetalpur Road, Gokak Mill Compound, Alkapuri, Vadodara 390020, Gujarat
- Share registrar
- MUFG Intime India Pvt. Ltd
- Keeps the register of shareholders and handles transfers and dividend payments